EP1045905A2 - Adn codant il-17rh et polypeptides il-17rh - Google Patents
Adn codant il-17rh et polypeptides il-17rhInfo
- Publication number
- EP1045905A2 EP1045905A2 EP99903032A EP99903032A EP1045905A2 EP 1045905 A2 EP1045905 A2 EP 1045905A2 EP 99903032 A EP99903032 A EP 99903032A EP 99903032 A EP99903032 A EP 99903032A EP 1045905 A2 EP1045905 A2 EP 1045905A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- polypeptides
- molecular weight
- protein
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Definitions
- the invention is directed to purified and isolated IL-17RH polypeptides, the nucleic acids
- polypeptides antibodies generated against these polypeptides, fragmented peptides derived from
- proteins are routinely analyzed using techniques such as electrophoresis, sedimentation,
- Protein molecular weight standards are commercially available to assist in the estimation of molecular weights of unknown protein samples (New England Biolabs Inc. Catalog:130-131,
- Enzymatic fragmentation of a protein can be achieved by incubation of a protein
- composition of a protein with regard to its specific amino acid
- peptides possess unique charge characteristics that determine the isoelectric pH of the peptide.
- Multildent Internet site:
- Fragmentation of proteins is further employed for the production of fragments for amino acids
- fragmentation of proteins can be used in the preparation of peptides for mass spectrometry (W.J. Henzel et al.,
- modification sites e.g. phosphorylation
- the invention aids in fulfilling this need in the art.
- the invention encompasses an
- isolated nucleic acid molecule comprising the DNA sequence of SEQ ID NO:l and an isolated
- nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2.
- the invention also provides a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2.
- Double-stranded RNA and DNA variants of IL-17RH encompassed by the invention.
- a double-stranded RNA and DNA variants of IL-17RH encompassed by the invention.
- stranded DNA probe allows the detection of nucleic acid molecules equivalent to either strand of
- nucleic acid molecule Isolated nucleic acid molecules that hybridize to a denatured, double-
- stranded DNA comprising the DNA sequence of SEQ ID NO:l or an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2 under conditions of moderate
- the invention further encompasses isolated nucleic acid molecules derived by in vitro
- the invention also encompasses isolated nucleic acid
- the invention also encompasses recombinant vectors that direct the expression of these
- nucleic acid molecules and host cells transformed or transfected with these vectors.
- the invention also encompasses isolated polypeptides encoded by these nucleic acid
- polyclonal or monoclonal antibodies that bind to these polypeptides are encompassed by the
- the invention further encompasses methods for the production of IL-17RH
- polypeptides including culturing a host cell under conditions promoting expression
- polypeptides in bacteria, yeast, plant, and animal cells is encompassed by the invention.
- IL-17RH polypeptides as therapeutic agents for the treatment of diseases mediated by IL-17RH
- polypeptide counter-structure molecules are encompassed by the invention. Further, methods of using IL-17RH polypeptides in the design of inhibitors thereof are also an aspect of the invention.
- the invention further encompasses the fragmented peptides produced from IL-17RH
- the invention also encompasses a method for the visualization of IL-17RH polypeptide
- fragmented peptides thereof as molecular weight markers that allow the estimation of the
- IL-17RH polypeptides encompasses methods for using IL-17RH polypeptides and fragmented peptides thereof as
- invention also encompasses methods for using IL- 17RH polypeptides and fragmented peptides
- Figure 1 is the nucleotide sequence of IL-17RH DNA, SEQ ID NO:l.
- Figure 2 is the amino acid sequence of IL-17RH polypeptide, SEQ ID NO:2.
- a cDNA encoding human IL-17RH polypeptide has been isolated and is disclosed in
- polypeptides comprising polypeptides; host cells transfected or transformed with the expression vectors; biologically
- IL- 17RH functions in human IL- 17 receptor (IL- 17R)
- signaling enables the design of assays to detect inhibitors of IL-17R activity.
- IL-17RH DNA was originally seen as three partial EST clones in the public databases.
- the ESTs were re-sequenced and found to be divergent from one another.
- the consensus cDNA The consensus cDNA
- SEQ ID NO:l encodes IL-17RH polypeptide (SEQ ID NO:2), which exhibits 24%
- homo logy occurs within a portion of the IL-17R known to be within the cytoplasmic domain.
- IL-17RH polypeptide encodes a receptor, which is related to the IL-17R; it can
- the cytoplasmic domain indicates that IL-17RH polypeptide is capable of signaling. Therefore,
- IL-17RH polypeptide can induce NFkB and regulate the production of heterologous cytokines.
- polypeptides can be accomplished utilizing fusion of sequences encoding IL-17RH polypeptides
- a fusion is a fusion of sequences encoding an IL-17RH polypeptide to
- construction of the insertion contains a termination codon adjoining the carboxyl terminal codon
- a DNA fragment can be generated by PCR
- oligonucleotide primers generates a blunt-ended fragment of DNA that can be isolated by
- This PCR product can be ligated together with pMAL-p2 (digested with
- Another preferred embodiment of the invention is the use of IL-17RH polypeptides as
- the IL-17RH polypeptide together with a sample protein, can be
- the unique amino acid sequence of IL-17RH (SEQ ID NO:2) specifies a
- molecular weight marker serves particularly well as a molecular weight marker for the estimation
- Another preferred embodiment of the invention is the use of IL-17RH fragmented peptide
- Isolated and purified IL-17RH polypeptide can be treated with cyanogen
- polypeptide molecular weight markers with cyanogen bromide generates a unique set of IL-
- each peptide determines its molecular weight.
- treatment of IL-17RH polypeptide with cyanogen bromide comprises 3 fragmented peptides of at
- the peptide encoded by amino acids 1-112 of SEQ ID NO:2 has a
- SEQ ID NO:2 has a molecular weight of approximately 10,451 Daltons.
- cyanogen bromide generates a unique set of IL-17RH fragmented peptide molecular weight
- IL-17RH fragmented peptide molecular weight markers have
- the IL-17RH fragmented peptide molecular weight markers can be used as
- the unique amino acid sequence of IL-17RH specifies a molecular weight of
- the IL-17RH fragmented peptide molecular weight markers serve as the IL-17RH fragmented peptide molecular weight markers. Therefore, the IL-17RH fragmented peptide molecular weight markers serve as the IL-17RH fragmented peptide molecular weight markers.
- sample protein and the IL-17RH polypeptide can be any suitable polypeptide.
- the sample protein and the IL-17RH polypeptide can be any suitable polypeptide.
- fragmented peptides from both the IL-17RH polypeptide and the sample protein can be any fragmented peptides from both the IL-17RH polypeptide and the sample protein.
- Fragmented peptides on the gel can be visualized using a conventional
- the IL-17RH fragmented peptide molecular weight markers can be used as
- molecular weight markers serve particularly well as molecular weight markers for the estimation
- markers can be generated from IL-17RH polypeptide using enzymes that cleave the polypeptide
- An isolated and purified IL-17RH polypeptide can be treated with Achromobacter
- protease I under conventional conditions that result in fragmentation of the IL-17RH polypeptide
- Achromobacter protease I generates a unique set of IL-17RH fragmented peptide molecular
- weight markers The distribution of lysine residues determines the number of amino acids in each peptide and the unique amino acid composition of each peptide determines its molecular
- treatment of IL-17RH polypeptide with Achromobacter protease I comprises 12 fragmented
- the peptide encoded by amino acids 15-24 of SEQ ID NO:2 has a molecular weight of
- the peptide encoded by amino acids 25-45 of SEQ ID NO:2 has a
- SEQ ID NO:2 has a molecular weight of approximately 1 , 192 Daltons.
- amino acids 57-69 of SEQ ID NO:2 has a molecular weight of approximately 1 ,404 Daltons.
- the peptide encoded by amino acids 170-103 of SEQ ID NO:2 has a molecular weight of
- the peptide encoded by amino acids 109-122 of SEQ ID NO:2 has
- the peptide encoded by amino acids 179-190 of SEQ ID NO:2 has a molecular
- ID NO:2 has a molecular weight of approximately 1,223 Daltons.
- amino acids 207-219 of SEQ ID NO:2 has a molecular weight of approximately 1,416 Daltons.
- the peptide encoded by amino acids 227-238 of SEQ ID NO:2 has a molecular weight of
- Achromobacter protease I generates a unique set of IL-17RH fragmented peptide molecular
- weight markers have molecular weights of approximately 1,167; 2,635; 1,192; 1,404; 4,096;
- sample protein can be resolved by denaturing polyacrylamide gel electrophoresis by
- the sample protein The IL-17RH fragmented peptide molecular weight markers serve
- sample protein and the IL-17RH polypeptide can be any suitable polypeptide.
- the sample protein and the IL-17RH polypeptide can be any suitable polypeptide.
- IL-17RH polypeptide The IL-17RH fragmented peptide molecular weight markers and the
- fragmented peptides derived from the sample protein are resolved by denaturing polyacrylamide
- molecular weight markers can be used as molecular weight markers in the estimation of the
- weight markers serve particularly well as molecular weight markers for the estimation of the
- monoclonal and polyclonal antibodies against IL-17RH are provided.
- polypeptides can be generated.
- Balb/c mice can be injected intraperitoneally on two occasions at
- mice are then assayed by conventional dot blot technique or antibody capture (ABC) to determine which animal is best to fuse. Three weeks later, mice are
- mice Three days later, mice are sacrificed and spleen cells fused with Ag8.653 myeloma cells
- mice spleen cells serum-free media and fused to mouse spleen cells at a ratio of three spleen cells to one myeloma
- the fusing agent is 50% PEG: 10% DMSO (Sigma). Fusion is plated out into twenty 96-
- 17RH polypeptide or peptides are added to each well, incubated for 60 minutes at room
- antibodies generated against IL-17RH and fragmented peptides are generated against IL-17RH and fragmented peptides.
- polypeptide or fragmented peptide molecular weight markers can be mixed with a molar excess
- Polypeptides can be transferred to a suitable protein binding membrane,
- polypeptides on the membrane can be visualized using two different methods that allow a
- polypeptide or fragmented peptide molecular weight markers can be visualized using antibodies
- polypeptide fragments since small peptides may not contain immunogenic epitopes. It is furthermore than immunogenic epitopes.
- the sample protein is visualized using a conventional staining procedure.
- the molar ratio of molar fraction is visualized using a conventional staining procedure.
- markers is such that the conventional staining procedure predominantly detects the sample
- the level of IL-17RH polypeptide or fragmented peptide molecular weight markers is
- sample protein between 2 and 100,000 fold. More preferably, the preferred molar excess of sample protein to
- IL-17RH polypeptide molecular weight markers is between 10 and 10,000 fold and especially
- the IL- 17RH polypeptide or fragmented peptide molecular weight markers can be used
- peptide molecular weight markers serve particularly well as molecular weight and isoelectric
- polypeptide or fragmented peptide molecular weight markers The ability to simultaneously
- sample protein under identical conditions allows for increased accuracy in the determination of
- IL-17RH polypeptide or fragmented peptide molecular weight In another embodiment, IL-17RH polypeptide or fragmented peptide molecular weight
- markers can be used as molecular weight and isoelectric point markers in the estimation of the
- sample protein with a cleavage agent. It is understood of course that many techniques can be
- IL- 17RH polypeptide molecular weight markers encompassed by invention can have
- variable molecular weights depending upon the host cell in which they are expressed.
- yeast two-hybrid system For example, the yeast two-hybrid system
- IL- 17RH screen for inhibitors of IL- 17RH as follows.
- the screen can be modified so that IL-
- microtiter plate to couple an easily detected indicator to the other component.
- IL-17RH polypeptides according to the invention are useful for the structure-
- Antibodies immunoreactive with IL-17RH polypeptides and in particular, monoclonal
- antibodies can be useful for inhibiting IL-17RH polypeptide activity in vivo and for detecting the
- IL-17RH polypeptides refers to a genus of polypeptides that
- IL-17RH polypeptides refers
- the isolated and purified IL-17RH polypeptide according to the invention has a
- IL-17RH polypeptides can be varied by fusing additional peptide sequences to both the amino acids
- IL-17RH polypeptides can be used to enhance the amino and carboxyl terminal ends of IL-17RH polypeptides.
- IL-17RH polypeptides or aid in the purification of the protein.
- peptides of IL-17RH polypeptides generated by enzymatic or chemical treatment.
- isolated and purified means that the IL-17RH polypeptide
- molecular weight markers or fragments thereof are essentially free of association with other
- proteins or polypeptides for example, as a purification product of recombinant host cell culture
- substantially purified refers to a mixture that contains IL-17RH polypeptide molecular weight markers or
- substantially purified IL-17RH polypeptides or fragments thereof can be used as molecular
- purified refers to either the “isolated and purified” form of IL-17RH
- nucleotide sequence refers to a polynucleotide molecule in the form of a separate
- RNA isolated at least once in substantially pure form i.e., free of contaminating endogenous
- IL-17RH polypeptide "variant" as referred to herein means a polypeptide substantially
- variant amino acid sequence preferably
- IL-17RH polypeptide amino acid sequence is at least 80% identical to a native IL-17RH polypeptide amino acid sequence, most preferably
- the percent identity can be determined, for example, by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et
- the preferred default parameters for the GAP program include: (1) a unary
- comparison matrix (containing a value of 1 for identities and 0 for non-identities) for
- Variants can comprise conservatively substituted sequences, meaning that a given amino
- conservative substitutions include substitution of one aliphatic residue for another, such as He,
- Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as
- Naturally occurring IL-17RH variants are also encompassed by the invention.
- proteolytic cleavage of the IL-17RH polypeptides Variations attributable to proteolysis include,
- the invention provides isolated and purified, or homogeneous, IL-17RH
- polypeptides both recombinant and non-recombinant.
- 17RH polypeptides that can be used as molecular weight markers can be obtained by mutations
- amino acid sequence can be accomplished by any of a number of conventional methods.
- Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a
- mutant sequence flanked by restriction sites enabling ligation to fragments of the native
- oligonucleotide-directed site-specific mutagenesis procedures can be used.
- IL-17RH polypeptides can be modified to create IL-17RH polypeptide derivatives by
- PEG polyethylene glycol
- Covalent derivatives of IL-17RH polypeptides can be prepared by linking the chemical moieties
- IL-17RH polypeptides within the scope of this invention include covalent or aggregative conjugates of IL-17RH polypeptides or peptide fragments with other proteins or polypeptides,
- N-terminal or C-terminal fusions such as by synthesis in recombinant culture as N-terminal or C-terminal fusions.
- the conjugate can comprise a signal or leader polypeptide sequence (e.g. the ⁇ -factor leader of
- IL-17RH polypeptide conjugates can comprise peptides added to facilitate purification
- IL-17RH polypeptides include, for example, poly-His or the
- the invention further includes IL-17RH polypeptides with or without associated native-
- COS-1 or COS-7 cells can be similar to or significantly different from a native
- IL-17RH polypeptide in molecular weight and glycosylation pattern, depending upon the choice
- E. coli provides non-glycosylated molecules. Glycosyl groups can be removed through
- 17RH polypeptides can be incubated with a molar excess of glycopeptidase (Boehringer
- N-glycosylation sites in eukaryotic polypeptides are characterized by an amino acid triplet Asn-X-Y, wherein X is any
- nucleotide sequence encoding these triplets will result in prevention of attachment of
- EP 212,914 discloses
- KEX2 protease processing sites are inactivated by deleting, adding, or substituting residues to
- Lys-Lys pairings are considerably less susceptible to KEX2 cleavage, and conversion
- the invention further encompasses isolated fragments and oligonucleotides derived from
- the invention also encompasses polypeptides
- Nucleic acid sequences within the scope of the invention include isolated DNA and RNA
- conditions of moderate or severe stringency and which encode IL-17RH polypeptides.
- conditions of moderate stringency as known to those having ordinary skill in the art, and
- nitrocellulose filters 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of
- Conditions of high stringency are defined as hybridization conditions as above, and with
- wash solution salt concentration can be adjusted as necessary according to factors such as the
- a DNA sequence can vary from that shown in SEQ ID NO:l and
- variant DNA sequences can result from silent mutations (e.g., occurring during PCR
- amplification or can be the product of deliberate mutagenesis of a native sequence.
- the invention thus provides equivalent isolated DNA sequences encoding IL-17RH
- polypeptides selected from: (a) DNA derived from the coding region of a native mammalian IL-
- polypeptides encoded by such DNA equivalent sequences are encompassed by the invention.
- 17RH polypeptides encoded by such DNA include, but are not limited to, IL-17RH polypeptide
- IL-17RH polypeptide-binding proteins such as the anti-IL-17RH polypeptide antibodies
- a solid phase such as a column chromatography matrix or a
- phase contacting surface can be accomplished by any means, for example, magnetic
- microspheres can be coated with IL-17RH polypeptide-binding proteins and held in the
- polypeptides on their surface bind to the fixed IL-17RH polypeptide-binding protein and
- releasing positively selected cells from the solid phase are known in the art and encompass, for
- enzymes are preferably non-toxic and non-injurious to the
- cells and are preferably directed to cleaving the cell-surface binding partner.
- cells first can be incubated with a biotinylated IL-17RH polypeptide-binding protein. Incubation
- periods are typically at least one hour in duration to ensure sufficient binding to IL-17RH
- the resulting mixture then is passed through a column packed with avidin-coated beads, whereby the high affinity of biotin for avidin provides the binding of the IL-17RH
- polypeptide-binding cells to the beads.
- avidin-coated beads Use of avidin-coated beads is known in the art. See
- the bound cells is performed using conventional methods.
- IL-17RH polypeptide-binding proteins are anti-semiconductor proteins
- IL-17RH polypeptide antibodies and other proteins that are capable of high-affinity binding of
- IL-17RH polypeptides A preferred IL-17RH polypeptide-binding protein is an anti-IL-17RH
- IL-17RH polypeptides can exist as oligomers, such as covalently linked or non-
- Oligomers can be linked by disulfide bonds formed between
- cysteine residues on different IL-17RH polypeptides are cysteine residues on different IL-17RH polypeptides.
- IL-17RH polypeptide dimer is created by fusing IL-17RH polypeptides to the Fc region of an
- the Fc polypeptide preferably is fused to the C-terminus of a soluble IL-17RH
- polypeptide comprising only the extracellular domain.
- IL-17RH polypeptide:Fc fusion proteins are allowed to assemble much like antibody
- IL-17RH polypeptides divalent IL-17RH polypeptides. If fusion proteins are made with both heavy and light chains of
- an antibody it is possible to form an IL-17RH polypeptide oligomer with as many as four IL- 17RH polypeptides extracellular regions.
- polypeptide domains with a peptide linker polypeptide domains with a peptide linker
- polypeptides can be prepared using well known methods.
- the expression vectors include an IL-
- nucleotide sequences such as those derived from a mammalian, microbial, viral, or insect gene.
- regulatory sequences include transcriptional promoters, operators, or enhancers, an
- a promoter functionally relates to the IL-17RH DNA sequence.
- a promoter functionally relates to the IL-17RH DNA sequence.
- nucleotide sequence is operably linked to an IL-17RH DNA sequence if the promoter nucleotide
- the desired host cells usually conferred by an origin of replication, and a selection gene by
- transformants which transformants are identified can additionally be incorporated into the expression vector.
- IL-17RH polypeptides can be incorporated into expression vectors.
- a DNA sequence for a signal peptide (secretory leader) can be fused in-frame to the IL-
- a signal peptide that is functional in the intended host comprising the signal peptide.
- the signal peptide can be any amino acid sequence that influences extracellular secretion of the IL-17RH polypeptide.
- the signal peptide can be
- Suitable host cells for expression of IL-17RH polypeptides include prokaryotes, yeast or
- Prokaryotes include gram negative or gram positive organisms, for example, E. coli or
- Suitable prokaryotic host cells for transformation include, for example, E. coli, Bacillus
- subtilis subtilis, Salmonella typhimurium, and various other species within the genera Pseudomonas,
- polypeptide can include an N-terminal methionine residue to facilitate expression of the
- the N-terminal Met can be cleaved from
- Expression vectors for use in prokaryotic host cells generally comprise one or more
- a phenotypic selectable marker gene is, for example, a
- Examples of useful expression vectors for prokaryotic host cells include those
- pBR322 contains genes for ampicillin and tetracycline resistance and thus provides
- vectors include, for example, pKK223-3 (Pharmacia Fine).
- proteins these would include pMAL-p2 and pMAL-c2 vectors that are used for the expression of
- vectors include ⁇ -lactamase (penicillinase), lactose promoter system (Chang et al., Nature
- particularly useful prokaryotic host cell expression system employs a phage ⁇ P L promoter and a
- thermolabile repressor sequence Plasmid vectors available from the American Type
- IL-17RH DNA may be cloned in- frame into the multiple cloning site of an ordinary
- the vector would contain an inducible promoter upstream of
- fusion partner such as
- plasmid may be propagated in a variety of strains of E. coli.
- the bacterial cells are propagated in growth
- IPTG isopropyl-b-D-thiogalactopyranoside
- the cells are harvested by pelleting in a centrifuge, e.g. at 5,000 x G for
- the pelleted cells may be resuspended in ten
- inclusion bodies can be purified away from the soluble proteins by pelleting in
- Tris-HCl pH 8)/l% Triton X-100 and then dissolved in 50 mM Tris-HCl (pH 8)/8 M urea/ 0.1
- the protein of interest will, in most cases, be the most abundant protein in the
- This protein may be "refolded" into the active conformation by
- initial purification may be carried out
- hexahistidine-tagged fusion proteins may be partially purified
- IL-17RH polypeptides alternatively can be expressed in yeast host cells, preferably from
- Saccharomyces genus e.g., S. cerevisiae
- Other genera of yeast such as Pichia , K. lactis,
- Yeast vectors will often contain an origin of
- replication sequence from a 2 ⁇ yeast plasmid, an autonomously replicating sequence (ARS), a
- Suitable promoter sequences for yeast vectors include, among others,
- isomerase 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase,
- phosphoglucose isomerase phosphoglucose isomerase
- glucokinase phosphoglucokinase
- yeast expression are further described in Hitzeman, EPA-73,657 or in Fleer et. al., Gene,
- E. coli can be constructed by inserting DNA sequences from pBR322 for selection and
- yeast -factor leader sequence can be employed to direct secretion of an IL-17RH
- the ⁇ -factor leader sequence is often inserted between the promoter sequence and
- yeast hosts suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to
- a leader sequence can be modified near its 3' end to contain one or more
- Trp + transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 ⁇ g/ml adenine, and
- Yeast host cells transformed by vectors containing ADH2 promoter sequence can be
- a rich medium is one
- Mammalian or insect host cell culture systems could also be employed to express
- mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651)
- CHO hamster ovary
- HeLa cells HeLa cells
- BHK ATCC CRL 10
- 1/EBNA-l cell line (ATCC CRL 10478) derived from the African green monkey kidney cell line
- Lipofectamine (Gibco/BRL) or Lipofectamine-
- electroporation can be used to transfect mammalian cells using conventional procedures
- DHFR reductase resistance
- a suitable host strain for DHFR selection can be CHO strain DX-
- a plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only
- selectable markers that can be incorporated into an expression vector include cDNAs conferring
- Cells harboring the vector can be any suitable antibiotics, such as G418 and hygromycin B.
- Cells harboring the vector can be any antibiotics, such as G418 and hygromycin B.
- Cells harboring the vector can be any suitable antibiotics, such as G418 and hygromycin B.
- vectors can be excised from viral genomes.
- Commonly used promoter sequences and enhancers are commonly used promoter sequences and enhancers
- sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human
- cytomegalo virus DNA sequences derived from the SV40 viral genome, for example, SV40
- Viral early and late promoters are particularly useful because both are easily obtained from
- a viral genome as a fragment which can also contain a viral origin of replication (Fiers et al.,
- fragments can also be used, provided the approximately 250 bp sequence extending from the
- Hind III site toward the Bgl I site located in the SV40 viral origin of replication site is included.
- mammalian expression vectors include such elements as the expression augmenting sequence
- EASE EASE element
- TPL tripartite leader
- VA gene RNAs from Adenovirus 2
- DHFR selectable marker
- Exemplary expression vectors that employ dicistronic mRNAs are pTR-
- pCAVNOT A useful high expression vector, pCAVNOT, has been described by Mosley et al., Cell
- the vectors can be derived from retroviruses. In place of the
- a heterologous signal sequence can be added, such as the signal sequence
- IL-17RH polypeptides can be substantially purified, as indicated
- SDS-PAGE SDS-polyacrylamide gel electrophoresis
- One process for producing IL-17RH polypeptides comprises culturing a host cell
- 17RH polypeptide is then recovered from culture medium or cell extracts, depending upon the
- recombinant protein will vary according to such factors as the type of host cells employed and
- concentrate can be applied to a purification matrix such as a gel filtration medium.
- an anion exchange resin can be employed, for example, a matrix or substrate
- the matrices can be acrylamide, agarose,
- dextran cellulose or other types commonly employed in protein purification.
- cellulose cellulose or other types commonly employed in protein purification.
- cation exchange step can be employed.
- Suitable cation exchangers include various insoluble
- matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.
- hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other
- aliphatic groups can be employed to further purify IL-17RH polypeptides.
- IL-17RH polypeptides can be removed from an affinity
- Recombinant protein produced in bacterial culture is usually isolated by initial disruption
- Microbial cells can be employed for final purification steps.
- Microbial cells can be disrupted by any convenient
- Transformed yeast host cells are preferably employed to express IL-17RH polypeptides
- Urdal et al. (J. Chromatog. 296:111, 1984). Urdal et al. describe two sequential, reversed-phase
- IL-17RH polypeptide molecular weight markers can be analyzed by methods including
- polypeptides can serve as molecular weight markers using such analysis techniques to assist in
- IL-17RH polypeptides can be subjected to fragmentation into peptides by chemical and
- Chemical fragmentation includes the use of cyanogen bromide to cleave
- fragmentation includes the use of a protease such as Asparaginylendopeptidase,
- Endoproteinase Asp-N, or Endoproteinase Lys-C under conventional conditions to result in
- Asparaginylendopeptidase can cleave specifically on
- Arginylendopeptidase can cleave specifically on the carboxyl side of the arginine residues
- Achrombobacter protease I can cleave specifically on the
- Trypsin can cleave specifically on the carboxyl
- aureus V8 protease can cleave specifically on the carboxyl side of the aspartic and glutamic acid
- Endoproteinase Asp-N can cleave specifically on the amino side of the asparagine
- Endoproteinase Lys-C can cleave specifically on
- the resultant fragmented peptides can be analyzed by methods including sedimentation,
- IL-17RH polypeptides can serve as molecular weight markers using such analysis techniques to
- molecular weight markers are preferably between 10 and 237 amino acids in size. More
- IL-17RH fragmented peptide molecular weight markers are between 10 and 100
- markers between 10 and 50 amino acids in size and especially between 10 and 35 amino acids in
- IL-17RH fragmented peptide molecular weight markers between 10
- polypeptide and sample protein under identical conditions can allow for a direct comparison of
- polypeptide can also result in complete fragmentation of the sample protein.
- IL-17RH polypeptides and fragmented peptides thereof possess unique
- isoelectric focusing The technique of isoelectric focusing can be further combined with other
- IL-17RH polypeptides and fragmented peptides thereof can be used in such
- sample protein can be assembled from IL-17RH polypeptides and peptide fragments thereof.
- Kits also serve to assess the degree of fragmentation of a sample protein.
- kits can be varied, but typically contain IL-17RH polypeptide and fragmented peptide
- kits can contain IL-17RH polypeptides wherein a site
- kits can contain reagents for
- Kits can further contain antibodies directed against IL-17RH polypeptides or fragments thereof.
- Antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence
- RNA or DNA capable of binding to a target IL-17RH mRNA sequence (forming a
- Antisense or sense oligonucleotides can be made according to the invention.
- Antisense or sense oligonucleotides according to the invention.
- present invention comprise a fragment of the coding region of IL-17RH cDNA (SEQ ID NO:l).
- Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to
- cDNA sequence for a given protein is described in, for example, Stein and Cohen, Cancer Res.
- RNA translation
- DNA transcription
- antisense oligonucleotides thus can be used
- Antisense or sense oligonucleotides further include
- oligonucleotides having modified sugar-phosphodiester backbones or other sugar
- oligonucleotides with resistant sugar linkages are stable in vivo
- oligonucleotides that are covalently linked to organic moieties, such as those
- target nucleic acid sequence such as poly-(L- lysine).
- intercalating agents such as
- ellipticine, and alkylating agents or metal complexes can be attached to sense or antisense
- oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the
- Antisense or sense oligonucleotides can be introduced into a cell containing the target
- nucleic acid sequence by any gene transfer method, including, for example, CaPO 4 -mediated
- DNA transfection electroporation, or by using gene transfer vectors such as Epstein-Barr virus.
- Antisense or sense oligonucleotides are preferably introduced into a cell containing the target
- nucleic acid sequence by insertion of the antisense or sense oligonucleotide into a suitable
- Suitable retroviral vectors include, but are not limited to, the
- DCT5 A vectors designated DCT5 A, DCT5B and DCT5C (see PCT Application US 90/02656).
- Sense or antisense oligonucleotides also can be introduced into a cell containing the
- Suitable ligand binding molecules include, but are not limited to,
- cell surface receptors include growth factors, other cytokines, or other ligands that bind to cell surface
- conjugation of the ligand binding molecule does not substantially interfere
- a sense or an antisense oligonucleotide can be introduced into a cell
- oligonucleotide- lipid complex containing the target nucleic acid sequence by formation of an oligonucleotide- lipid complex
- the sense or antisense oligonucleotide-lipid complex is preferably
- Isolated and purified IL-17RH polypeptides or a fragment thereof can also be useful itself
- IL-17RH polypeptides can be
- IL-17RH DNA, IL-17RH polypeptides, and antibodies against IL-17RH polypeptides can be any suitable IL-17RH DNA, IL-17RH polypeptides, and antibodies against IL-17RH polypeptides.
- these reagents can serve as markers for cell
- RNA or proteins specific or tissue specific expression of RNA or proteins.
- these reagents can be used
- IL-17RH IL-17RH RNA or polypeptides.
- DNA can be used to determine the chromosomal location of IL-17RH DNA and to map genes in
- IL-17RH DNA can also be used to examine genetic
- IL-17RH DNA can be further used to
- IL-17RH DNA and polypeptides can be used to select for those
- IL-17RH polypeptides can also be used as a reagent to identify (a) any protein that IL-
- polypeptides could be used by coupling recombinant protein to an affinity matrix, or by using
- IL-17RH polypeptides When used as a therapeutic agent, IL-17RH polypeptides can be formulated into
- IL-17RH polypeptides can be any suitable polypeptide.
- IL-17RH polypeptides can be any suitable polypeptide.
- diluents e.g., Tris-HCl, acetate, phosphate
- preservatives e.g., sodium bicarbonate
- compositions can contain IL-17RH
- polypeptides complexed with polyethylene glycol (PEG), metal ions, or incorporated into PEG
- PEG polyethylene glycol
- polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, etc., or incorporated
- IL-17RH polypeptides and peptides based on the
- amino acid sequence of IL-17RH can be utilized to prepare antibodies that specifically bind to
- IL-17RH polypeptides IL-17RH polypeptides.
- antibodies is meant to include polyclonal antibodies,
- Antibodies are defined to be specifically binding if
- binding partners or antibodies can be readily determined using conventional techniques, for example
- Polyclonal antibodies can be readily generated from a variety of sources, for example,
- polypeptides can be enhanced through the use of an adjuvant, for example, Freimd's complete or
- CIEP immuno-electrophoresis
- ELISA immuno-sorbent assays
- dot blot assays dot blot assays
- sandwich assays see U.S. Patent Nos.
- Monoclonal antibodies can be readily prepared using well-known procedures, see for
- mice are injected intraperitoneally at least once, and preferably at least twice at about 3 week
- Mouse sera are then assayed by conventional dot blot technique or antibody capture (IL-17RH) to determine which animal is best to fuse.
- IL-17RH antibody capture
- mice are given an intravenous boost of IL-17RH
- the myeloma cells are washed several times in media and fused to
- mouse spleen cells at a ratio of about three spleen cells to one myeloma cell.
- PEG polyethylene glycol
- the fused cells can then be allowed to grow for approximately eight days.
- Supernatants from the fused cells can then be allowed to grow for approximately eight days.
- resultant hybridomas are collected and added to a plate that is first coated with goat anti-mouse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ADN codant Ies polypeptides IL-17RH et procédés d'utilisation desdits polypeptides codés.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7107398P | 1998-01-09 | 1998-01-09 | |
US71073P | 1998-01-09 | ||
PCT/US1999/000515 WO1999035263A2 (fr) | 1998-01-09 | 1999-01-08 | Adn codant il-17rh et polypeptides il-17rh |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1045905A2 true EP1045905A2 (fr) | 2000-10-25 |
Family
ID=22099081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99903032A Withdrawn EP1045905A2 (fr) | 1998-01-09 | 1999-01-08 | Adn codant il-17rh et polypeptides il-17rh |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1045905A2 (fr) |
JP (1) | JP2003502006A (fr) |
AU (1) | AU2315099A (fr) |
CA (1) | CA2317817A1 (fr) |
WO (1) | WO1999035263A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
EP1015488B1 (fr) * | 1997-09-17 | 2009-09-09 | Human Genome Sciences, Inc. | Proteine de type recepteur d'interleukine 17 |
US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
US8133734B2 (en) | 1999-03-16 | 2012-03-13 | Human Genome Sciences, Inc. | Kit comprising an antibody to interleukin 17 receptor-like protein |
TWI322154B (en) * | 2000-03-16 | 2010-03-21 | Amgen Inc | Il-17 receptor like molecules and uses thereof |
US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
WO2002008285A2 (fr) * | 2000-06-22 | 2002-01-31 | Amgen, Inc. | Molecules il-17 et leurs utilisations |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449758A (en) * | 1993-12-02 | 1995-09-12 | Life Technologies, Inc. | Protein size marker ladder |
JP4373495B2 (ja) * | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Il−17受容体 |
-
1999
- 1999-01-08 EP EP99903032A patent/EP1045905A2/fr not_active Withdrawn
- 1999-01-08 WO PCT/US1999/000515 patent/WO1999035263A2/fr not_active Application Discontinuation
- 1999-01-08 CA CA002317817A patent/CA2317817A1/fr not_active Abandoned
- 1999-01-08 AU AU23150/99A patent/AU2315099A/en not_active Abandoned
- 1999-01-08 JP JP2000527647A patent/JP2003502006A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9935263A3 * |
Also Published As
Publication number | Publication date |
---|---|
AU2315099A (en) | 1999-07-26 |
CA2317817A1 (fr) | 1999-07-15 |
WO1999035263A2 (fr) | 1999-07-15 |
WO1999035263A3 (fr) | 1999-09-10 |
JP2003502006A (ja) | 2003-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050233355A1 (en) | Human cDNAs encoding polypeptides having kinase functions | |
EP1045905A2 (fr) | Adn codant il-17rh et polypeptides il-17rh | |
WO1999033983A1 (fr) | Adn et polypeptides v201 | |
US20090017492A1 (en) | SVPH1-26 DNA and polypeptides | |
EP1045914B1 (fr) | Svph1-8 proteinase humaine specifique aux testicules | |
US20050101768A1 (en) | H14 DNA and polypeptides | |
EP1105485B1 (fr) | Adn humain il-1 epsilon et polypeptides | |
AU745623B2 (en) | V196 DNA and polypeptides | |
US7217553B2 (en) | Nucleic acids encoding human adamalysin SVPH1-8 | |
WO2000008178A2 (fr) | Molecules d'adn murin codant pour des polypeptides presentant des fonctions kinases | |
US7250276B2 (en) | Human IL-1 epsilon DNA and polypeptides | |
WO1999033984A1 (fr) | Adn et polypeptides v197 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000807 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020801 |